Cargando…
Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
OBJECTIVE: To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D), documented pre-existing cardiovascular disease (CVD), and a history of hypertension. RESEARCH DESIGN AND METHODS: Patient...
Autores principales: | Cefalu, William T., Leiter, Lawrence A., de Bruin, Tjerk W.A., Gause-Nilsson, Ingrid, Sugg, Jennifer, Parikh, Shamik J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831907/ https://www.ncbi.nlm.nih.gov/pubmed/25852208 http://dx.doi.org/10.2337/dc14-0315 |
Ejemplares similares
-
Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
por: Strojek, Krzysztof, et al.
Publicado: (2014) -
Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
por: Raz, Itamar, et al.
Publicado: (2009) -
Extended insulin boluses cannot control postprandial glycemia as well as a standard bolus in children and adults using insulin pump therapy
por: Lopez, Prudence, et al.
Publicado: (2014) -
Effect of Supervised Progressive Resistance-Exercise Training Protocol on Insulin Sensitivity, Glycemia, Lipids, and Body Composition in Asian Indians With Type 2 Diabetes
por: Misra, Anoop, et al.
Publicado: (2008) -
Optimizing Postprandial Glycemia in Pediatric Patients With Type 1 Diabetes Using Insulin Pump Therapy: Impact of glycemic index and prandial bolus type
por: O'Connell, Michele A., et al.
Publicado: (2008)